Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

LAVAL, Quebec and TARRYTOWN, N.Y., April 24, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for the treatment of […]

Read More »

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

NORTH CHICAGO, Ill., April 24, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company’s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The NDA is for the treatment of […]

Read More »

World’s first malaria vaccine moves closer to use in Africa

(Reuters) – The world’s first malaria vaccine, made by GlaxoSmithKline, could be approved by international regulators for use in Africa from October after final trial data showed it offered partial protection for up to four years. The shot, called RTS,S and designed for children in Africa, would be the first licensed human vaccine against a […]

Read More »

Aerie Pharma shares battered as eye drug fails study

<span class="articleLocation”>(Reuters) – Aerie Pharmaceuticals Inc lost nearly three-quarters of its value after the company said its lead experimental eye drug failed a late-stage study. The eye drop, Rhopressa, did not lower pressure inside the eye as much as timolol, a commonly prescribed drug, the company said. Increased pressure in the eye is often a […]

Read More »

U.S. cancer survival rates improving

  (This version of the Feb 19 story replaces paragraphs two, six and seven with new text to clarify that the statistics reflected the decline in risk of death from cancer, not an increase in survival.)   By Andrew M. Seaman (Reuters Health) – The proportion of people surviving years after a cancer diagnosis is […]

Read More »

Common asthma steroids linked to side effects in adrenal glands

<span class="articleLocation”>(Reuters Health) – After stopping steroids commonly prescribed for asthma and allergies, a significant number of people may experience signs of malfunctioning in the adrenal glands, a European study finds. So-called adrenal insufficiency can be dangerous, especially if the person’s body has to cope with a stress like surgery, injury or a serious illness, […]

Read More »

Ovary removal may improve breast cancer survival with gene mutation

<span class="articleLocation”>(Reuters Health) – Women with a gene mutation that puts them at a high risk of breast and ovarian cancers have better survival odds if their ovaries and fallopian tubes are removed soon after a breast cancer diagnosis, suggests a new study from Canada. Women with the BRCA1 gene mutation who were diagnosed with […]

Read More »

High morale linked to longer survival among elderly

A pensioner sits in a residential home for the elderly in Emmenbruecke near Lucerne December 7, 2007. Reuters/Christian Hartmann <span class="articleLocation”>(Reuters Health) – Whether it is cause or effect is unclear, but high morale seems to go along with a longer life, according to a new Scandinavian study. Among people 85 years and older, those […]

Read More »

Targazyme, Inc., Announces FDA Concurrence on Targazyme's Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

SAN DIEGO, CA–(Marketwired – April 23, 2015) – Targazyme, Inc., announced today that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company’s Special Protocol Assessment (SPA) application for its Phase 3 registration trial. This pivotal trial is designed to evaluate the efficacy of TZ101-treated cells in patients with hematologic […]

Read More »

AstraZeneca, Juno latest to collaborate on immuno-oncology drugs

(Reuters) – A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body’s immune system to kill cancer cells. The partnership between AstraZeneca’s research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom